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this techniques is not well established. We sought to assess the long-term effects of
intrarterial infusion of BMMC in patients with CLI.
Methods: from September 2004 to December 2007 intrarterial infusion of BMMC was
performed in 28 subjects with CLI (fontain grade 3 and 4, 17 men and 11 women). The
mean age was 60 years. 50% of subject in the study population had ischemic defects in
the Lower limb, 53.5% diabetes mellitus, 42.8% ischemic heart disease, 67.8% arterial
hypertension, 21.4% thrombangitis obliterans and 50% hyperlipoproteinemia.
Results: Major amputation was performed during follow up in 2 subjects 3 months after
BMMC implantation. 11 of the 14 fourteen subject with defect had healed (79%) and the
Fontaine grade improved to grade 2B in 22 subjects (84.6%). In 2 patients (7.6%) resting
pain remained in spite of defects healing but were well controlled with analgesics. In 2
subjects the size of the defect was reduced one year after BMMC treatment but did not
heal. The mean ankle brachial index was improved with treatment (0.54 vs 0.67, p
0.0001) and the mean tpO2 was improved (14.9 vs 37.2 mmHg, p 0.0001). The
overall quality of life assessed using SF-36 questionnaire was also dramatically improved
after one year (p 0.0001).After 5 years of follow up 14 patients had died (50%) due to
multiple cardiovascular comorbidities. 11 individual (39%) were without resting pain and
in the fontain class 2B. 3 patients (10%) were asymptomatic. None of the patient in the
surviving group underwent major amputation or had ischemic defect.
Conclusions: Transcatheter intra-arterial administration of BMMC is a suitable alterna-
tive for treatment of patients with critical limb ischemia. However, the midterm benefits
of this method are limited by long term unfavorable outcome due to high mortality caused
by cardiovascular comorbidities
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Background: Distal embolization (DE) events are commonly reported in percutaneous
atherectomy procedures. Embolic protection (EP) devices reduce these events. This study
compared inpatient hospital costs and resource utilization in two non-coronary (presumed
lower extremity) atherectomy patient populations: (1) a DE event group, and (2) an EP
group.
Methods: All inpatient discharges for atherectomy of non-coronary vessels (ICD-9-CM
procedure code 39.50) were selected from a comprehensive hospital admissions database
(Premier Perspective CY2005-20 10). DE patients were identified using ICD-9-CM
diagnosis codes (444.XX, 434.0, and 434.1). Patients receiving EP devices were identified
using a billing data keyword search. Discharges in the DE and EP groups were propensity
matched adjusting for age, gender, race and severity scores. Inpatient mortality, length of
stay, operating room (OR) time, and costs were compared between the groups.
Results: After propensity matching DE and EP groups, there were n1,497 matched
pairs. The inpatient mortality rate was significantly higher in DE compared to EP (2.7%
vs. 1.3%, p0.05). Hospital stay averaged 1.4 days longer in the DE patients (p0.05).
Room and board, surgery and pharmacy costs were significantly higher for DE (p0.05).
OR time was 24 minutes longer for DE patients. Total costs were higher but not
significant for the DE group ($24,326 vs. $23,594, p0.38). As a reference, the total rate
of embolic events detected in this inpatient population was 13.5 percent.
Conclusions: The use of embolic protection is strongly associated with lower inpatient
mortality rates, shorter hospital stays, and shorter OR times. Cumulatively, these findings
demonstrate embolic protection devices may significantly reduce consumption of hospital
resources.
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Background: Recent registries and randomized trials support the role of percutaneous
revascularization in patients with critical limb ischemia (CLI) and life limiting claudica-
tion (LLC) due also to infragenicular atherosclerotic disease. However, the percutaneous
transluminal angioplasty (PTA) may result in high restenosis rate and target lesion
revascularization.Promising results are coming from ond randomised controlled study an
single center registries using drug eluting balloon (DEB) in this arterial district.
Methods: Between December 2008 and December 2010, 75 (48 males) consecutive
patients underwent percutaneous revascularization of below the knee(BTK) arteries in our
institution due to CLI(58[72.5%]) and LLC(17[27.5%]). Functional status was Rutheford
class 3 in 4 (5%) patients, class 4 in 24(30%) patients, class 5 in 37(50%), and class 6 in
10(15%). All patients(98 lesions) were treated predilating with an undersized standard
balloon and then with Pacltaxel Eluting Balloon In.Pact Amphirion (Medtronic).No
limitation in number of vessels treated, lesion length were considered (mean treated length
8925 mm). A total occlusion was the target lesion in 47% of cases. In 22 cases above
the knee arteries were previously treated.Polpliteal artery was the target lesion in 17 cases,
anterior tibial artery in 28 cases, posterior tibial artery in 23 cases, peroneal artery in 16
cases.
Results: Procedural success, meaning angiographic evidence of restored antegrade flow,
was achieved in 70 (94%) patients. Bail-out stenting for flow limiting dissection or abrupt
target vessel occlusion was needed in 7 patients(10%). Procedural complication:distal
embolization 2(2.5%),access site complication 1(1.5%), intra-hospital mortality
1(1,5%).The rate of angiographic restenosis at twelve months was 24% (n15). Only
symptomatic patients were planned for a reintervention(n9). One-year primary patency
was 76%(n52); secondary patency was 91% (n61).
Conclusions: The outcome of this single center experience suggest that the use of drug
eluting balloon for percutaneous transluminal angioplasty of below the knee arterial
lesions is feasible, safe, and provides favourable one-year clinical results in patients with
CLI.
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Background: Drug eluting stents (DES) have become the standard therapy for coronary
interventions, however its benefits on peripheral artery disease are not as clear, particularly
in below-knee peripheral arterial disease.
Methods: All randomized controlled trials of drug eluting stents in below-knee peripheral
artery disease were sought in PubMed, and Cochrane databases during May 2012. Data
was extracted by 3 reviewers and analyzed with RevMan 5.1 software.
Results: Four randomized controlled trials were found. Our analysis demonstrated a clear
benefit in patency manifested by a freedom of target lesion revascularization up to four
times higher with DES (p0.001, Figure1) and an improvement of at least one level on
the Rutherford classification up to two times higher at 6 to 12 months (p0.005, Figure
2). There was a non significant trend favoring DES in reducing major amputations (Figure
3) and death incidence was similar.
Conclusions: Our meta-analysis shows that DES significantly improves patency and
symptoms when compared to BMS for the revascularization of below-knee arterial
disease.
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Background: Peripheral interventional therapy to treat occlusive disease for patients
with symptomatic claudication is considered standard clinical practice. The present study
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was designed to evaluate long-term vascular biology response to fluorocopolymer
(poly-vinylidene fluoride hexafluoroproprylene, PVDF-HFP) coated self-expandable
low-dose paclitaxel-eluting nitinol stent (FP-PES, 0.167g/mm2) in a porcine ilio-
femoral artery model.
Methods: FP-PES (6, 7 or 8mm x 80 mm, n12 at 30 and 180d, n13 at 90d) or BMS
(n12 at 30, 90 and 180d) with identical stent length and size were implanted in the
ilio-femoral arteries of 37 pigs. Complete histomorphometric and histopathologic analy-
ses were performed after termination of animals. In addition, an in vivo pharmacokinetic
(PK) study was conducted for FP-PES (n8/time-point) at 4, 10, 30, 60, 90 and 180d.
Paclitaxel levels in systemic blood and major organs were also evaluated.
Results: Paclitaxel released steadily without burst phenomenon. Paclitaxel levels were
below quantifiable levels in both blood and major organs at all-time points. Neointimal
thickness was significantly inhibited by FP-PES (0.350.09, 0.550.15 mm) compared
to BMS (0.700.25, 1.000.25 mm) at 30 and 90d (p0.001, respectively), yielding
reductions of in-stent stenosis by 48.1% and 51.9% for FP-PES versus BMS (P0.005
and 0.0001, respectively). No difference in any of the histomorphometric parameters
was apparent at 180d. Stents from both groups were completely re-endothelialized and
there was no thrombus apparent in either group at any time point., Drug effect was
observed as higher expression for both fibrin deposition and para-strut inflammation
scores in FP-PES vs. BMS (p0.05) at all time-points although the absolute scores were
low for both groups.
Conclusions: Maintaining long-term patency after peripheral endovascular therapy
remains a challenge. The FP-PES decreased neointimal formation at 30d and 90d
compared to BMS, with a comparable vascular healing response and no evidence of
systemic paclitaxel.
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Background: Little data are available regarding the association between the site of the
leg wound occurring from critical limb ischemia (CLI) and the prognosis of hemodialysis
patients with CLI after isolated infrapopliteal balloon angioplasty(BA).
Methods: This study used data obtained from a multi-center retrospective study.Among
serial 884 CLI patients who underwent BA for primary treatment of isolated infrapopliteal
lesions from 2004 to 2011, subjects were 449 serial patients on hemodialysis with a CLI
wound (ulcer or gangrene). The site of the CLI wound was observed before the initial
treatment and all wounds were confirmed to be either confined distal from the
metatarsals-phalanx(MP) joint to the tips of the toes or proximal from the MP joint to the
ankle. Patients with wounds confined distal to the MP joint were defined as the Distal(D)
group (109 patients, 109 limbs, age: 66.510.4 years) and those whose wounds were not
confined here were defined the Proximal(P) group (340 patients, 340 limbs, age: 69.29.6
years). The two groups were compared for average 3.01.5 years clinical outcomes.
Results: There was no significant difference in the percentage of patients with diabetes
mellitus (75.2 vs. 76.5%), contralateral CLI limb (23.9 vs. 21.5%), or coronary artery
disease (57.8vs. 58.2%). For the target vessel, there was no significant difference in the
ratio of target vessels with total occlusion (69.9 vs. 70.0%).The percentage of getting
direct flow to wounds site based on the angiosome concept was lower in P group than that
of D group (P:45.9 vs. D:63.5%, P0.01). At the 3-year clinical results, the P group had
high rates of major amputation (P:21.2 vs. D:12.3%, P0.05), while there was no
difference in the percentage of death (39.4% vs. 31.4%). The P group had a significantly
lower major amputation-free survival rate estimated using the Kaplan-Meier methods
compared to D group (P: 31.0 vs. D: 45.6%, Logrank; p0.01).
Conclusions: The limb salvage rate of hemodialysis patients after isolated infrapopliteal
BA whose CLI wounds were confined distal to the MP joint was better than that of
patients who had wounds proximal to the MP joint, but the mortality of all hemodyalisis
patents with CLI wounds was high.
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Background: Primary stenting from common iliac artery (CIA) to external iliac artery
(EIA), jailing internal iliac artery (IIA), has a risk of compromised IIA.The purpose of this
study was to evaluate in-hospital and 12 month clinical outcome in patients treated with
stent deployment at EIA-IIA bifurcation, especially in comparison between crossover
stenting strategy and non-crossover stenting one, focusing on fate of jailed IIA.
Methods: A retrospective study was performed of patients who underwent endovascular
intervention for iliac artery presented from February 2000 to April 2011. Subject was 60
patients/57 lesion with iliac arteries who underwent attempted recanalization with the
self-expandable or balloon expandable stent. And we divided these subjects into the two
following groups; 44 patients (45 lesions) treated with Crossover stenting with jailed of
IIA and 13 patients (15 lesions) underwent non-crossover stenting without coverage of
IIA. We have investigated patients background/lesion background/Bifurcation type/EVT
strategy/Clinical outcome/acute and chronic occlusion rate of IIA.
Results: No significant difference was detected in the baseline demographic, angio-
graphic, and lesion characteristics. Technical success obtained 100% .Regarding acute or
12 months occlusion rate of IIA, no difference was seen between Cross-over group and
Non-cross-over goup(acute: 4% vs 0%,12-month :4% vs 0%.
Conclusions: Occlusion rate of internal iliac(IIA) were extremely low and complains of
pelvic organ ischemia were not seen when treated with either crossover or non-crossover
stenting, for IIA in acute phase as well as 12 month.
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Background: Chronic total occlusions (CTO) of the SFA are a challenging subset of
lesions encountered in peripheral interventions. CTO’s of the SFA are commonly crossed
either with an intraluminal (IL) or re-entry device assisted subinitimal (SI) approach
followed by stenting. Even though both these techniques have a high immediate
procedural success rate the long term outcomes of each approach are not well studied.
Methods: We studied 112 patients (144 limbs) with obstructive SFA disease treated with
nitinol self-expanding stents; there were 77 (53.5%) limbs with CTO. We analyzed
in-stent restenosis (ISR) rates, as well as: age, sex, GFR, presence of diabetes and
coronary artery disease, lesion lengths, TASC Classification, and stent diameter in 3
subgroups of patients: without CTO; with CTO crossed IL; and with CTO crossed SI.
Results: In CTO group, 22 (28%) limbs were treated with SI approach, and 55 (72%)
using IL. During mean follow up period of 27.6 17 months, ISR was diagnosed in: 21
(31.3%) pts of non-CTO; 20 (36.4%) of IL CTO; and 13 (59.1%) of SI CTO, Figure 1.
The number of pts with diabetes was (p0.001) higher in CTO IL compared to CTO SI
group, 73.8% versus 26% respectively. The mean lesion length was 206.4 110 mm in
IL and 245.9  118 mm (p0.17) in SI. There was no significant difference in other
parameters.
Conclusions: We observed similar SFA ISR rates between pts without and with CTO if
CTO was crossed using IL approach. Device assisted SI approach in CTO pts was
associated with higher ISR compared to non-CTO pts and trend to higher ISR compared
to CTO IL group.
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Background: Interim analysis of the first 1000 patients treated with Misago RX nitinol
stent in iliac and femoropopliteal arteries at 1 year follow-up.
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